STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.

Commissioner Makary and CBER Director Prasad stopped by the 20 May ODAC meeting. (Sue Sutter)

More from US Advisory Committees

More from Product Reviews